BidaskClub upgraded shares of Alder BioPharmaceuticals (NASDAQ:ALDR) from a sell rating to a hold rating in a research note released on Thursday morning.
ALDR has been the topic of a number of other research reports. Mizuho reaffirmed a buy rating and issued a $32.00 target price on shares of Alder BioPharmaceuticals in a research note on Friday, September 15th. ValuEngine raised Alder BioPharmaceuticals from a strong sell rating to a sell rating in a research note on Saturday, September 30th. Cowen started coverage on Alder BioPharmaceuticals in a research note on Tuesday, September 26th. They issued an outperform rating and a $20.00 target price on the stock. Canaccord Genuity started coverage on Alder BioPharmaceuticals in a research note on Thursday, October 26th. They issued a buy rating and a $20.00 target price on the stock. Finally, Royal Bank of Canada started coverage on Alder BioPharmaceuticals in a research note on Thursday, September 14th. They issued an outperform rating and a $17.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $27.71.
Shares of Alder BioPharmaceuticals (NASDAQ ALDR) traded down $0.45 during trading hours on Thursday, hitting $12.95. The stock had a trading volume of 1,198,400 shares, compared to its average volume of 1,202,400. The stock has a market cap of $877.50, a price-to-earnings ratio of -2.42 and a beta of 2.48. Alder BioPharmaceuticals has a fifty-two week low of $8.60 and a fifty-two week high of $25.45.
Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.29. During the same period in the previous year, the business posted ($0.70) earnings per share. equities research analysts anticipate that Alder BioPharmaceuticals will post -5.14 earnings per share for the current fiscal year.
In other Alder BioPharmaceuticals news, insider Mark James Litton sold 16,520 shares of the business’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $12.33, for a total value of $203,691.60. Following the completion of the transaction, the insider now directly owns 116,452 shares in the company, valued at approximately $1,435,853.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.60% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of ALDR. Quantitative Systematic Strategies LLC acquired a new position in Alder BioPharmaceuticals in the 3rd quarter valued at $132,000. Legal & General Group Plc raised its holdings in Alder BioPharmaceuticals by 2.6% in the 2nd quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 400 shares during the last quarter. SG Americas Securities LLC raised its holdings in Alder BioPharmaceuticals by 109.4% in the 2nd quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 8,140 shares during the last quarter. Jane Street Group LLC acquired a new position in Alder BioPharmaceuticals in the 3rd quarter valued at $184,000. Finally, Voya Investment Management LLC raised its holdings in Alder BioPharmaceuticals by 8.4% in the 2nd quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock valued at $255,000 after acquiring an additional 1,734 shares during the last quarter. Institutional investors own 96.80% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Alder BioPharmaceuticals (ALDR) Upgraded at BidaskClub” was reported by Equities Focus and is the sole property of of Equities Focus. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.equitiesfocus.com/2018/01/08/alder-biopharmaceuticals-aldr-upgraded-at-bidaskclub.html.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.